BioCardia doses first patient in CardiALLO Phase I/II trial of BCDA-03

BioCardia announced that the first patient was enrolled and treated in its CardiALLO Allogeneic Mesenchymal Cell Therapy Phase I/II trial for the treatment of patients with New York Heart Association Class II and III ischemic heart failure of reduced ejection fraction. “The initiation of the CardiALLO MSC clinical trial for HFrEF is a significant milestone in our efforts to improve patients’ lives through the development of new treatments that target the underpinnings of heart disease,” said Peter Altman, Ph.D., BioCardia’s President and CEO. “We are grateful for the support of study sites, patients and families who are actively engaged with BioCardia in our efforts to explore the potential of BCDA-03 as a novel treatment for ischemic HFrEF. We look forward to continuing this close partnership as we actively enroll additional patients in the CardiALLO MSC Study. Similar to our autologous CardiAMP cell therapy, which this allogenic cell therapy compliments, there are no requirements for immunosuppression, antiarrhythmic drugs, or open chest surgery.”